Idiopathic hypereosinophilic syndromes and rare dysimmune conditions associated with hyper-eosinophilia in practice: An innovative multidisciplinary approach.

Benralizumab HES Hypereosinophilic syndrome Mepolizumab Multidisciplinary Precision medicine

Journal

The World Allergy Organization journal
ISSN: 1939-4551
Titre abrégé: World Allergy Organ J
Pays: United States
ID NLM: 101481283

Informations de publication

Date de publication:
Aug 2024
Historique:
received: 15 12 2023
revised: 29 05 2024
accepted: 12 06 2024
medline: 19 8 2024
pubmed: 19 8 2024
entrez: 19 8 2024
Statut: epublish

Résumé

Hypereosinophilic syndromes (HES) represent a group of rare dis-immune conditions characterized by blood hyper-eosinophilia and eosinophilic related burden. Especially the idiopathic subtype (I-HES) is particularly difficult to diagnose because of its heterogeneous clinical presentation, the lack of specific findings on physical exam, lab tools, and imaging informative enough to unequivocally confirm the diagnosis and the overlap with other entities, including eosinophilic organ-diseases or systemic dis-immune conditions other than I-HES (from atopy to eosinophilic granulomatosis with polyangiitis [EGPA], the last often extremely difficult to distinguish from HES). Taken together, all the features mentioned above account for an extremely difficult early recognition HES and on-time referral to a specialized centre. The referral itself is challenging due to a not univocal specialist identification, because of the variability of physicians managing HES in different settings (including allergist/clinical immunologist, haematologist, internal medicine doctors, pulmonologist, rheumatologist). Furthermore, the approach in terms of personalized treatment identification and follow-up plan (timing, organ assessment), is poorly standardized. Further translational and clinical research is needed to address the mentioned unmet needs, but on practical grounds increasing the overall clinicians' awareness on HES and implementing healthcare pathways for HES patients represent a roadmap that every clinician might try to realize in his specific setting. The present review aims at providing an overview about the current challenges and unmet needs in the practical approach to HES and rare hypereosinophilic allergo-immunological diseases, including a proposal for an innovative multidisciplinary organizational model.

Identifiants

pubmed: 39156600
doi: 10.1016/j.waojou.2024.100928
pii: S1939-4551(24)00059-0
pmc: PMC11327453
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

100928

Informations de copyright

© 2024 The Author(s).

Déclaration de conflit d'intérêts

The authors declare that they have no competing interests in relation to the topic of the manuscript.

Auteurs

Marco Caminati (M)

Department of Medicine, University of Verona, Verona, Italy.
Allergy Unit and Asthma Center, Verona Integrated University Hospital, Verona, Italy.

Lucia Federica Carpagnano (LF)

University of Verona, Verona Italy.

Chiara Alberti (C)

Pharmacy Unit, Verona Integrated University Hospital, Verona, Italy.

Francesco Amaddeo (F)

Unit of Psychosomatics and Medical Psychology, Verona Integrated University Hospital, and Department of Neurosciences, Biomedicine and Movement, University of Verona, Italy.

Riccardo Bixio (R)

Rheumatology Unit, Verona Integrated University Hospital, Verona, Italy.

Federico Caldart (F)

Gastroenterology and Digestive Endoscopy Unit, The Pancreas Institute, Verona Integrated University Hospital, Verona, Italy.

Lucia De Franceschi (L)

Department of Medicine, University of Verona, Verona, Italy.
Unit of Internal Medicine B, Verona Integrated University Hospital, Verona Italy.

Micol Del Giglio (M)

Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.

Giuliana Festi (G)

Pulmonology Unit, Verona Integrated University Hospital, Verona Italy.

Simonetta Friso (S)

Department of Medicine, University of Verona, Verona, Italy.
Unit of Internal Medicine B, Verona Integrated University Hospital, Verona Italy.

Luca Frulloni (L)

Department of Medicine, University of Verona, Verona, Italy.
Gastroenterology and Digestive Endoscopy Unit, The Pancreas Institute, Verona Integrated University Hospital, Verona, Italy.

Paolo Gisondi (P)

Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.

Mauro Krampera (M)

Department of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona, Verona, Italy.

Giuseppe Lippi (G)

Section of Clinical Biochemistry and School of Medicine, University of Verona, Verona, Italy.

Claudio Micheletto (C)

Pulmonology Unit, Verona Integrated University Hospital, Verona Italy.

Giorgio Piacentini (G)

Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, Pediatric Clinic, University of Verona, Verona, Italy.

Patrick Pinter (P)

Unit of Otolaryngology, Head and Neck Department, University of Verona, Verona, Italy.

Maurizio Rossini (M)

Department of Medicine, University of Verona, Verona, Italy.
Rheumatology Unit, Verona Integrated University Hospital, Verona, Italy.

Michele Schiappoli (M)

Allergy Unit and Asthma Center, Verona Integrated University Hospital, Verona, Italy.

Cristina Tecchio (C)

Department of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona, Verona, Italy.

Laura Tenero (L)

Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, Pediatric Clinic, University of Verona, Verona, Italy.

Elisa Tinazzi (E)

Unit of Internal Medicine B, Verona Integrated University Hospital, Verona Italy.

Gianenrico Senna (G)

Department of Medicine, University of Verona, Verona, Italy.
Allergy Unit and Asthma Center, Verona Integrated University Hospital, Verona, Italy.

Matilde Carlucci (M)

Health Directorate, Verona Integrated University Hospital, Verona, Italy.

Classifications MeSH